Modification of the anticancer drug tamoxifen to avoid CYP2D6 polymorphism

The prodrug tamoxifen (TAM) is the most widely used drug to treat breast cancer, and is metabolised to the active 4-hydroxy derivatives dominantly by hepatic CYP2D6. However, the application to pat ...

[1]  Yusuke Nakamura,et al.  Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapy , 2008, Cancer science.

[2]  R. Elledge,et al.  Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Minoti Sharma,et al.  Biotransformation of tamoxifen in a human endometrial explant culture model. , 2003, Chemico-biological interactions.

[4]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Christopher I. Bayly,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation , 2002, J. Comput. Chem..

[6]  P. Lønning,et al.  Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer , 2002, Breast Cancer Research and Treatment.

[7]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[8]  Donald G Truhlar,et al.  Density functionals with broad applicability in chemistry. , 2008, Accounts of chemical research.

[9]  Jacopo Tomasi,et al.  Continuum solvation models: A new approach to the problem of solute’s charge distribution and cavity boundaries , 1997 .

[10]  K. Lunetta,et al.  Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. , 2000, Cancer research.

[11]  M. Churchwell,et al.  DNA Adduct Formation in the Livers of Female Sprague−Dawley Rats Treated with Toremifene or α-Hydroxytoremifene , 2007 .

[12]  Gert Vriend,et al.  Making optimal use of empirical energy functions: Force‐field parameterization in crystal space , 2004, Proteins.

[13]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[14]  H. Rochefort,et al.  Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. , 1982, Cancer research.

[15]  E. Gillam,et al.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[17]  K. Pollow,et al.  Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients , 1991, American journal of clinical oncology.

[18]  J. Tomasi,et al.  The IEF version of the PCM solvation method: an overview of a new method addressed to study molecular solutes at the QM ab initio level , 1999 .

[19]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[20]  G. Vriend,et al.  Fast empirical pKa prediction by Ewald summation. , 2006, Journal of molecular graphics & modelling.

[21]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[22]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[23]  Jacopo Tomasi,et al.  A new integral equation formalism for the polarizable continuum model: Theoretical background and applications to isotropic and anisotropic dielectrics , 1997 .

[24]  Chang-Guo Zhan,et al.  Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. , 2011, Journal of the American Chemical Society.

[25]  E. Engelsman,et al.  Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study. , 1975, British medical journal.

[26]  S. Wingren,et al.  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer , 2007, Breast Cancer Research.

[27]  Sason Shaik,et al.  Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. , 2005, Chemical reviews.

[28]  H. Kuramochi.  Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. , 1996, Journal of medicinal chemistry.

[29]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[30]  C. Osborne,et al.  Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.

[31]  A. LaCroix,et al.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. , 2010, Journal of the National Cancer Institute.

[32]  P. Neven,et al.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[33]  T. Powles,et al.  32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. , 1995, Carcinogenesis.

[34]  Jacopo Tomasi,et al.  Evaluation of Solvent Effects in Isotropic and Anisotropic Dielectrics and in Ionic Solutions with a Unified Integral Equation Method: Theoretical Bases, Computational Implementation, and Numerical Applications , 1997 .

[35]  J. Dawson,et al.  Heme-Containing Oxygenases. , 1996, Chemical reviews.

[36]  Lei He,et al.  Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  G. Sledge,et al.  Effects of high dose raloxifene in selected patients with advanced breast carcinoma , 2000, Cancer.

[38]  W. McGuire,et al.  Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.

[40]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[41]  C. Falany,et al.  Steroid sulfation by expressed human cytosolic sulfotransferases , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  K. Turteltaub,et al.  Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. , 2002, Carcinogenesis.

[43]  Sason Shaik,et al.  Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. , 2004, Chemical reviews.

[44]  J. Cuzick,et al.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.

[45]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[46]  M. Jarman,et al.  A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. , 1994, Carcinogenesis.

[47]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[48]  L. Skoog,et al.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.

[49]  H. Bartsch,et al.  Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. , 2000, Carcinogenesis.

[50]  A. Buzdar,et al.  Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Evans,et al.  Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients , 2008, Clinical Cancer Research.

[52]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  D. Truhlar,et al.  The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals , 2008 .

[54]  J. Scheys,et al.  Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.

[55]  Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  B. Rattel,et al.  Preclinical data for Droloxifene. , 1994, Cancer letters.

[57]  Hui Chen,et al.  The directive of the protein: how does cytochrome P450 select the mechanism of dopamine formation? , 2011, Journal of the American Chemical Society.

[58]  L. Hutchins,et al.  Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. , 2002, Journal of the National Cancer Institute.

[59]  S. Shaik,et al.  A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome p450 enzymes. , 2003, Journal of the American Chemical Society.

[60]  D. Stevenson,et al.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[61]  Leif A. Eriksson,et al.  A Mechanistic Hypothesis for the Cytochrome P450-Catalyzed Cis-Trans Isomerization of 4-Hydroxytamoxifen: An Unusual Redox Reaction , 2011, J. Chem. Inf. Model..

[62]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[63]  L. Sternson,et al.  Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. , 1981, Biopharmaceutics & drug disposition.